PathAI

Machine learning on whole slide images is the entire company. The AIM product line consists of validated algorithms for quantitative biomarker assessment across commercially significant oncology targets, and the company reports having launched more than 20 AI products. The AISight platform is the delivery layer those models run inside, but the models are what customers and, evidently, acquirers are buying.

Positioned as quantitative assessment supporting pathologist interpretation rather than autonomous diagnosis, with the cleared platform used for primary diagnosis by a pathologist working inside it. The biopharma application is the more interesting oversight case: when a qualified tool scores liver biopsies as a trial endpoint, the algorithm's output becomes regulatory evidence rather than a suggestion a clinician can override, which is a materially different accountability structure that buyers and sponsors should understand as such.

The regulatory record forced and documented an unusual level of scrutiny. FDA qualification of the MASH tool as a Drug Development Tool required the agency to review the algorithm sufficiently to permit its use as a trial endpoint, which is a deeper examination than device clearance. The 2025 AISight Dx clearance included a Predetermined Change Control Plan, meaning model updates follow a pre agreed path rather than arriving silently, which is the same disciplined mechanism Qure AI holds in imaging. Peer reviewed publication history extends to a first manuscript in Hepatology.

Evidence sits across regulatory, commercial, and academic axes simultaneously. FDA and EMA qualification of AIM-MASH as the first AI powered pathology Drug Development Tool means two regulators independently accepted the algorithm as fit for endpoint assessment in registrational MASH studies. Commercial validation is substantial: a national reference laboratory acquired the diagnostics lab business and licensed the platform for its own pathology operations, and Roche entered a merger agreement valuing the company at up to roughly 1.05 billion dollars after a partnership dating to 2021. The company also built its own CAP and CLIA certified laboratory to support end to end trial work.

No published PHI framework or data governance disclosure was located. The data surface is broad, spanning clinical diagnostic slides at laboratory customers and trial specimens for biopharma sponsors, and the pending change of ownership makes current stewardship terms a question a buyer should resolve directly rather than assume.

No HIPAA or BAA commitment was located in public materials, though business associate status is structurally required given deployment in clinical diagnostic laboratories.

No SOC 2, HITRUST, or ISO 27001 attestation was located in the materials reviewed. Worth noting that a direct competitor in this category publishes a full certification set, so the absence here reflects disclosure practice rather than category norm.

Among the strongest regulatory positions in pathology AI, and notable for spanning two distinct regimes. On the device side, AISight Dx holds FDA 510(k) clearance and CE marking for primary diagnosis, with a 2025 clearance of the evolved platform incorporating a Predetermined Change Control Plan. On the drug development side, AIM-MASH received both FDA and EMA qualification as the first AI powered pathology Drug Development Tool, permitting sponsors to use it for endpoint assessment in registrational MASH studies, which is a different and in some respects higher bar than clearance. A dermatology product received Breakthrough Device Designation in March 2026, which expedites review and is not authorization.

No governance framework or bias evaluation was located. The relevant question for computational pathology is performance variation across scanner platforms, staining protocols, and laboratory practice, and no published analysis addresses it. An open question flagged by external analysts is whether platform neutrality survives the acquisition, since a diagnostics owner prioritizing its own assays could affect which third party algorithms run on the platform.

Integration targets the laboratory stack correctly, with connectivity to existing laboratory information systems and anatomic pathology workflows, whole slide image management covering storage, retrieval, and viewing, and both cloud and on premise deployment options for hospital and reference laboratory settings. The company also launched a global network of digital anatomic pathology laboratories. The acquirer's stated rationale centers on owning this image management layer, which is a fair read of where the platform's durable value sits. No named LIS integrations were enumerated.

Both cloud and on premise deployment are offered for hospital and reference laboratory settings, which is genuine flexibility and matters for laboratories with data locality constraints or large slide volumes. Specific tenancy and residency terms are not published, and deployment decisions may change under the acquiring organization.

No published pricing, and ownership is in transition. Roche entered a definitive merger agreement in May 2026 at 750 million dollars upfront plus up to 300 million in milestone payments, expected to close in the second half of 2026 subject to antitrust and regulatory approval, after which the company becomes part of Roche's Diagnostics division. Buyers should establish how existing licensing arrangements, including those with national reference laboratories, survive the transaction.

Two distinct customer bases with real depth in each: clinical diagnostic laboratories using the cleared platform for primary diagnosis, and biopharmaceutical sponsors using the interpretation modules and trial services for translational research and endpoint assessment. Clinical depth concentrates in oncology biomarkers with significant investment in liver disease through the MASH work, plus a dermatology product in development. This is a laboratory and research product with no provider clinical workflow surface.